Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer...
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
Biotech company, Mind Medicine Inc, is expanding its drug development pipeline with the launch of a programme to develop R(-)-MDMA for the treatment of social anxiety...
A novel MDMA-like chemical series have been identified with drug-like properties which will be developed to treat addiction.
A first-of-its-kind study will investigate the use of MDMA-assisted psychotherapy for the treatment of female Hypoactive Sexual Desire Disorder (HSDD).
The Multidisciplinary Association for Psychedelic Studies (MAPS) has received funding of $1.5m from Wasana Health in a first-of-its-kind collaboration to accelerate research into MDMA-assisted therapy for...
